---
schema_version: "secwatch.filing_event.v1"
accession: "0001606498-24-000016"
form_type: "8-K"
ticker: "AVNS"
cik: "0001606498"
company_name: "AVANOS MEDICAL, INC."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:07:24.904162+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Avanos Medical Q4 net sales $173.3M (-4.6% YoY); 2024 outlook $685-$705M revenue, adj. EPS $1.30-$1.45

## Summary
- Q4 net sales $173.3M (-4.6% YoY); full-year net sales $673.3M (-1.6%) on lower HA sales.
- Q4 GAAP diluted EPS $0.24 (vs $0.21); adjusted EPS $0.36 (vs $0.45). Full-year GAAP loss $(0.21) (vs $0.46 EPS); adjusted EPS $1.03 (vs $1.00).
- Free cash flow for 2023 was $14.6M, down from $71.6M in 2022; Q4 outflow $3.4M.
- Completed sale of respiratory health business (Oct 2) and acquired Diros Technology (July 24) to focus on Pain Management and Digestive Health.
- 2024 guidance: net sales $685-$705M (organic growth 3%-6%), adj. gross margin 59.5%-60.5%, adj. diluted EPS $1.30-$1.45.

## SEC filing metadata
- accession: 0001606498-24-000016
- form_type: 8-K
- ticker: AVNS
- cik: 0001606498
- company_name: AVANOS MEDICAL, INC.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1606498/000160649824000016/0001606498-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1606498/000160649824000016/avns-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001606498-24-000016
- JSON: https://secwatch.observer/filing/0001606498-24-000016.json
- Plain text: https://secwatch.observer/filing/0001606498-24-000016.txt

## Key facts
- Earnings Releases
  AVANOS MEDICAL, INC. reported fourth quarter and full-year 2023 results: revenue Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the, EPS Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share o.
  - Period: fourth quarter and full-year 2023
  - Revenue: Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the
  - EPS: Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share o
  - Result: reported results
  source text: Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the full-year, net sales from continuing operations decreased 1.6% to $673.3 million. • Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share of $0.21 per share a year ago, and fourth quarter adjusted diluted earnings per share from continuing operations were $0.36 compared to $0.45 in the prior year. 2023 full-year diluted loss per share from continuing operations were $0.21 compared to diluted earnings per share of $0.46 in the prior year, and adjusted diluted earnings per share from continuing operations were $1.03 compared to $1.00 in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1606498/000160649824000016/0001606498-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.